Insider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider Sells $165,829.94 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 11,366 shares of the company’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.59, for a total value of $165,829.94. Following the transaction, the insider directly owned 97,907 shares in the company, valued at approximately $1,428,463.13. The trade was a 10.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, May 14th, David Malcom Rodman sold 11,366 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $15.29, for a total transaction of $173,786.14.

Mineralys Therapeutics Price Performance

NASDAQ MLYS opened at $14.34 on Friday. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $18.38. The stock has a market capitalization of $934.68 million, a PE ratio of -3.84 and a beta of -0.30. The business has a 50 day simple moving average of $14.88 and a two-hundred day simple moving average of $13.09.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.23. On average, analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MLYS has been the topic of a number of recent analyst reports. Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They set a “hold” rating and a $15.00 price target on the stock. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Guggenheim set a $48.00 price objective on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, June 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Mineralys Therapeutics has a consensus rating of “Hold” and a consensus target price of $32.25.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. grew its position in Mineralys Therapeutics by 26.7% in the 1st quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company’s stock worth $97,619,000 after purchasing an additional 1,296,296 shares during the last quarter. SR One Capital Management LP increased its position in shares of Mineralys Therapeutics by 55.1% during the first quarter. SR One Capital Management LP now owns 3,127,933 shares of the company’s stock worth $49,672,000 after acquiring an additional 1,111,111 shares in the last quarter. Millennium Management LLC grew its position in Mineralys Therapeutics by 1,015.8% in the fourth quarter. Millennium Management LLC now owns 1,101,674 shares of the company’s stock valued at $13,562,000 after purchasing an additional 1,002,941 shares in the last quarter. Jennison Associates LLC grew its position in shares of Mineralys Therapeutics by 82.9% in the 1st quarter. Jennison Associates LLC now owns 1,979,033 shares of the company’s stock valued at $31,427,000 after acquiring an additional 897,027 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Mineralys Therapeutics by 42.1% in the 1st quarter. Vanguard Group Inc. now owns 2,035,506 shares of the company’s stock valued at $32,324,000 after acquiring an additional 603,464 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.